Minerva Neurosciences (NERV) Equity Average (2014 - 2026)
Minerva Neurosciences posted quarterly Equity Average of -$197.4 million for Q1 2026, down 619.82% year-on-year from $38.0 million in Q1 2025, and down 125.16% on a QoQ basis from -$87.7 million in Q4 2025.
Minerva Neurosciences (NERV) has 13 years of Equity Average data on file, last reported at -$197.4 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 619.82% year-over-year to -$197.4 million; the trailing twelve-month figure through Mar 2026 stood at -$197.4 million (down 619.82% YoY), and the FY2025 full-year result was -$83.2 million, down 207.37% from the prior year.
- Equity Average for Q1 2026 stood at -$197.4 million, down from -$87.7 million in the prior quarter.
- Across five years, Equity Average topped out at $3.6 million in Q1 2022 and bottomed at -$197.4 million in Q1 2026.
- The 5-year median for Equity Average is -$24.3 million (2023), against an average of -$36.4 million.
- The widest annual swing landed in 2023, when Equity Average tumbled 744.28%; it then grew 24.45% in 2025.
- A 5-year view of Equity Average shows it stood at -$17.1 million in 2022, then sank by 41.53% to -$24.3 million in 2023, then gained by 2.35% to -$23.7 million in 2024, then tumbled by 270.17% to -$87.7 million in 2025, then tumbled by 125.16% to -$197.4 million in 2026.
- The last three Equity Average figures came in at -$197.4 million (Q1 2026), -$87.7 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -197.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -197.38 Mn |
| Dec 31, 2025 | -87.66 Mn |
| Sep 30, 2025 | -33.34 Mn |
| Jun 30, 2025 | -30.63 Mn |
| Mar 31, 2025 | -27.42 Mn |
| Dec 31, 2024 | -23.68 Mn |
| Sep 30, 2024 | -33.08 Mn |
| Jun 30, 2024 | -40.54 Mn |
| Mar 31, 2024 | -32.52 Mn |
| Dec 31, 2023 | -24.25 Mn |
| Sep 30, 2023 | -16.28 Mn |
| Jun 30, 2023 | -19.56 Mn |
| Mar 31, 2023 | -23.32 Mn |
| Dec 31, 2022 | -17.14 Mn |
| Sep 30, 2022 | -11.31 Mn |
| Jun 30, 2022 | -4.56 Mn |
| Mar 31, 2022 | 3.62 Mn |
| Dec 31, 2021 | 18.03 Mn |
| Sep 30, 2021 | 32.12 Mn |
| Jun 30, 2021 | 40.77 Mn |
| Mar 31, 2021 | 49.02 Mn |
| Dec 31, 2020 | 55.34 Mn |
| Sep 30, 2020 | 57.48 Mn |
| Jun 30, 2020 | 37.78 Mn |
| Mar 31, 2020 | 23.20 Mn |
| Dec 31, 2019 | 41.65 Mn |
| Sep 30, 2019 | 61.40 Mn |
| Jun 30, 2019 | 72.35 Mn |
| Mar 31, 2019 | 83.84 Mn |
| Dec 31, 2018 | 95.83 Mn |
| Sep 30, 2018 | 106.03 Mn |
| Jun 30, 2018 | 115.98 Mn |
| Mar 31, 2018 | 126.45 Mn |
| Dec 31, 2017 | 130.89 Mn |
| Sep 30, 2017 | 114.10 Mn |
| Jun 30, 2017 | 102.16 Mn |
| Mar 31, 2017 | 106.13 Mn |
| Dec 31, 2016 | 109.56 Mn |
| Sep 30, 2016 | 116.87 Mn |
| Jun 30, 2016 | 93.63 Mn |
| Mar 31, 2016 | 60.98 Mn |
| Dec 31, 2015 | 59.19 Mn |
| Sep 30, 2015 | 65.72 Mn |
| Jun 30, 2015 | 71.41 Mn |
| Mar 31, 2015 | 62.97 Mn |
| Dec 31, 2014 | 54.11 Mn |
| Sep 30, 2014 | 42.97 Mn |